HC Wainwright Predicts Reduced Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright dropped their Q4 2026 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of $0.41 for the quarter, down from their previous forecast of $0.47. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The company had revenue of $192.57 million during the quarter, compared to the consensus estimate of $192.15 million. During the same quarter last year, the company earned $0.15 earnings per share. The business’s revenue was up 78.0% on a year-over-year basis.

TGTX has been the subject of a number of other research reports. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. Wall Street Zen downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. cut their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $50.00.

TG Therapeutics Stock Up 1.1%

Shares of NASDAQ:TGTX opened at $29.19 on Wednesday. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $46.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.89 and a current ratio of 4.10. The company’s fifty day moving average is $29.75 and its 200-day moving average is $31.48. The company has a market capitalization of $4.66 billion, a PE ratio of 10.54 and a beta of 1.87.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its position in shares of TG Therapeutics by 47.1% during the fourth quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock worth $47,989,000 after acquiring an additional 515,481 shares during the period. Corient Private Wealth LLC grew its stake in TG Therapeutics by 3.6% during the 4th quarter. Corient Private Wealth LLC now owns 41,764 shares of the biopharmaceutical company’s stock worth $1,245,000 after purchasing an additional 1,469 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in TG Therapeutics during the 4th quarter worth $212,000. Empowered Funds LLC purchased a new stake in TG Therapeutics during the 4th quarter worth about $1,698,000. Finally, nVerses Capital LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $250,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.